News

Press Releases

Current News and Historical Highlights

ALL
ALL
2026
2025
2024
2023
2022
2021
2020
2019
2018
2015
2014
Previous
Oct 21, 2026

Asahi Kasei Therapeutics Announces Late-Breaking Oral and Poster Presentations at IDWeek 2026

Oct 9, 2026

Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults

Oct 8, 2026

Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients

Sep 29, 2026

Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics

Aug 31, 2026

Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients

Jun 17, 2026

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Apr 22, 2026

Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients

Apr 15, 2026

Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026

US-AKTX-2600007 V1.0 6/26